CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark ...

A new study in The Journal of Immunology reveals how a high-fat diet may impair the immune system’s ability to respond to infection by impacting the function of neutrophils, one of the first immune ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

These cells have on their surface a range of receptors for inflammatory cytokines, including interferon gamma, TNF, IL-17 ... immunoselected using monoclonal antibodies to high purity and potency.

Biologics are medications made from antibodies that prevent certain ... agents bind to and block the protein called tumor necrosis factor-alpha (TNF-alpha). In people with UC, this protein causes ...